Neutrophil Extracellular Trap Components Associate with Infarct Size, Ventricular Function, and Clinical Outcome in STEMI

Table 4

NET marker levels according to adverse clinical events after 12-month follow-up.

	Adverse clinical event -	Adverse clinical event +
dsDNA (ng/ml)
Before PCI	450 (385, 538)	506 (415, 745)	0.022
After PCI	433 (380, 506)	499 (387, 630)	0.037
Day 1	360 (327, 406)	402 (376, 436)	0.005
After 4 months	338 (310, 371)	349 (318, 368)	0.833
MPO-DNA (OD)
Before PCI	0.239 (0.205, 0.294)	0.306 (0.196, 0.359)	0.210
After PCI	0.232 (0.203, 0.272)	0.225 (0.212, 0,254)	0.454
Day 1	0.230 (0.182, 0.341)	0.274 (0.189, 0.330)	0.484
After 4 months	0.195 (0.155, 0.247)	0.158 (0.140, 0.205)	0.045

Adverse clinical event is defined as a composite of death, myocardial infarction (MI), , stroke, or rehospitalization for heart failure. dsDNA: double-stranded deoxyribonucleic acid. MPO-DNA: myeloperoxidase-deoxyribonucleic acid. OD: optical density units. PCI: percutaneous coronary intervention.